Journal Information
Vol. 99. Issue 5.
Pages 773-775 (1 September 2024)
Visits
1584
Vol. 99. Issue 5.
Pages 773-775 (1 September 2024)
Letter - Therapy
Full text access
A case of generalized pustular psoriasis following Moderna/NIAID COVID-19 vaccination successfully treated with secukinumab
Visits
1584
Misaki Kusano
Corresponding author
k963@fmu.ac.jp

Corresponding author.
, Ryuto Mukaiyama, Toshiyuki Yamamoto
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Cases of generalized pustular psoriasis following mRNA coronavirus vaccination.
Full Text
Dear Editor,

Here, we present a case of the development of generalized pustular psoriasis (GPP) following COVID-19 vaccination in a patient with psoriasis vulgaris.

A 64-year-old woman was referred to our department, complaining of high fever, and erythemas with superficial pustules all over the body seven days after the third dose of Moderna/NIAID COVID-19 messenger RNA vaccination (mRNA-CV). She had received the first and second doses of Pfizer/BioNTech mRNA-CV. She had developed psoriasis vulgaris (PsV) about one and half years previously and had been treated with oral apremilast and topical calcipotriol hydrate at a nearby clinic under control. At the initial visit, a physical examination revealed multiple erythemas and small pustules with scales on the trunk and extremities, and edema was prominent on the bilateral lower legs (Fig. 1). A skin biopsy was performed from an erythema with pustules on the left thigh. Histopathology showed subcorneal aggregation of neutrophils surrounded by multilocular small pustules with spongiosis (Kogoj’s spongiform pustule) (Fig. 2). Blood test showed that C-reactive protein is high (7.80 mg/dL) and white blood cells were normal. Liver and kidney dysfunction was not observed. The patient was treated with secukinumab, resulting in a significant improvement of the rash after 2 months.

Fig. 1.

(A and B) Multiple erythemas and small pustules with scales on the trunk and extremities, and edema was prominent on both lower legs.

(0.17MB).
Fig. 2.

(A) Subcorneal pustule formation (Hematoxylin & eosin, ×20). (B) Subcorneal aggregation of neutrophils surrounded by multilocular small pustules with spongiosis (Kogoj’s spongiform pustule, ×200).

(0.31MB).

In recent years, there have been several reports of GPP following the mRNA-CV.1–8 As far as we searched, nine cases have been reported (Table 1). The average age was 52 years and the male-to-female ratio was 5:4. Seven of the nine patients had a history of psoriasis, whereas two patients developed GPP de novo. The duration from vaccination to onset of symptoms ranged from 4 to 21 days. mRNA vaccines were used in 7 of 9 cases (5 cases were Pfizer). Most patients developed pustular lesions after the first or second vaccination. Acitretin (n = 3), etretinate (n = 1), cyclosporine (n = 1), and biologics (n = 6) were used for treatment (overlapping). Regarding the biologics, secukinumab (n = 3), infliximab (n = 1), adalimumab (n = 1), and risankizumab (n = 1) were used. Two of the nine patients performed a sequencing analysis of genomic DNA derived from peripheral blood, which revealed no gene mutations in entire coding regions of IL36RN.8 In our case, IL36RN was not investigated.

Table 1.

Cases of generalized pustular psoriasis following mRNA coronavirus vaccination.

Author  Age  Sex  History  Vaccine  Dose  Days of onset  Treatment  IL-36RN 
Onsun N  72  Male  Psoriasis vulgaris  Inactivated vaccine  1st  acitretin,infliximab  – 
Elamin S  66  Female  None  DNA(Oxford-AstraZeneca)  1st  21  acitretin  – 
Perna D  40  Male  Psoriasis vulgaris  mRNA  1st  secukinumab  – 
Yamazaki K (in Japanese)  76  Male  Psoriasis vulgaris  Pfizer/BioNTech BNT162b2 mRNA  2nd  19  adalimumab  – 
Yatsuzuka K  65  Male  Generalized pustular psoriasis  mRNA   2nd  12  secukinumab  – 
Frioui R  20  Male  Psoriasis vulgaris  Pfizer/BioNTech BNT162b2 mRNA  1st  acitretin  – 
Pavia G  47  Female  Psoriasis vulgaris  Pfizer/BioNTech BNT162b2 mRNA  2nd  10  risankizumab  – 
Tachibana K  60  Female  Impetigo herpetiformis  Pfizer/BioNTech BNT162b2 mRNA  2nd  etretinate  none 
Tachibana K  18  Female  Psoriasis vulgaris  Pfizer/BioNTech BNT162b2 mRNA  1st  cyclosporine, secukinumab  none 
This case  64  Female  Psoriasis vulgaris  Moderna/NIAID mRNA-1273  3rd  secukinumab  – 

Several mechanisms have been proposed to exacerbate psoriasis by COVID-19 vaccination. One is the mechanism involving angiotensin converting enzyme (ACE). It is believed that the activity of ACE increases and causes an inflammatory cytokine storm by COVID-19 vaccination.9 The second is the activation of the toll-like receptor (TLR) pathway. Farkas et al.10 found that vaccines may activate dermal myeloid dendritic cells that play roles in the inflammatory psoriasis cascade. Dendritic cells differentiate T-cells into Th1 and Th17 cells by releasing inflammatory mediators and then trigger the release of downstream cytokines. These inflammatory cytokines are thought to be involved in the exacerbation of psoriasis,1 but further examination is necessary to clarify the mechanisms of GPP induction by COVID-19 vaccination.

Financial support

None declared.

Authors’ contributions

Misaki Kusano: Approval of the final version of the manuscript; critical literature review; data collection; analysis and interpretation; study conception and planning; management of studied cases; manuscript critical review; preparation and writing of the manuscript.

Ryuto Mukaiyama: Approval of the final version of the manuscript; critical literature review; manuscript critical review; preparation and writing of the manuscript.

Toshiyuki Yamamoto: Approval of the final version of the manuscript; critical literature review; data collection; analysis and interpretation; study conception and planning; manuscript critical review; preparation and writing of the manuscript.

Conflicts of interest

None declared.

References
[1]
N. Onsun, G. Kaya, B.G. Isik, B. Gunes.
A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report.
Health Promot Perspect., 11 (2021), pp. 261-262
[2]
S. Elamin, F. Hinds, J. Tolland.
De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine.
Clin Exp Dermatol., 47 (2022), pp. 153-155
[3]
D. Perna, J. Jones, C.R. Schadt.
Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine.
JAAD Case Rep., 17 (2021), pp. 1-3
[4]
K. Yamazaki, S. Nagata.
Practical Dermatology, 45 (2023), pp. 68-71
[5]
K. Yatsuzuka, M. Murakami, Y. Kuroo, M. Fukui, S. Yoshida, J. Muto, et al.
Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination.
J Dermatol, 49 (2022), pp. 454-458
[6]
R. Frioui, A. Chamli, A. Zaouak, Imen Hlel, F. Khanchel, S. Fenniche, et al.
A case of new-onset acute generalized pustular psoriasis following Pfizer-BioNTech COVID-19 vaccine.
Dermatol Therapy., 35 (2022),
[7]
G. Pavia, L. Gargiulo, F. Spinelli, J. Avagliano, M. Valenti, R.G. Borroni, et al.
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with Risankizumab.
J Eura Acad Dermatol Venereol, 36 (2022), pp. e502-e505
[8]
K. Tachibana, Y. Kawakami, M. Tokuda, S. Sato, S. Sugihara, T. Miyake, et al.
Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: two cases without mutations of IL36RN and CARD14 genes.
J Dermatol., 49 (2022), pp. e393-4
[9]
M. Shahidi-Dadras, M. Tabary, R.M. Robati, F. Araghi, S. Dadkhahfar.
Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?.
J Dermatolog Treat., 33 (2022), pp. 1175-1176
[10]
A. Farkas, G. Tonel, F.O. Nestle.
Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells.
Br J Dermatol, 158 (2008), pp. 921-929

Study conducted at the Fukushima Medical University, Fukushima, Japan.

Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.